Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 7INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 687Breast Neoplasms 585Neoplasms 468Colorectal Neoplasms 300Prostatic Neoplasms 263Neoplasm Metastasis 257Melanoma 242Ovarian Neoplasms 228Recurrence 216Lung Neoplasms 203Multiple Myeloma 196Lymphoma, Non-Hodgkin 155Pancreatic Neoplasms 154Leukemia, Myeloid, Acute 142Carcinoma, Hepatocellular 141Stomach Neoplasms 137Lymphoma 131Carcinoma, Renal Cell 128Glioblastoma 118Squamous Cell Carcinoma of Head and Neck 113Head and Neck Neoplasms 113Lymphoma, Follicular 106Leukemia, Lymphocytic, Chronic, B-Cell 99Small Cell Lung Carcinoma 96Lymphoma, Large B-Cell, Diffuse 96Leukemia 96Brain Neoplasms 91Carcinoma 82Uterine Cervical Neoplasms 77Triple Negative Breast Neoplasms 73

Interventions

radium Ra 223 dichloride 1bafetinib 1Mycobacterium w vaccine 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Hormone Refractory Prostate Cancer × Clear all
NCT00667199 2023-04-19

BAY88-8223, Does Response Study in HRPC Patients

Bayer

Phase 2 Completed
100 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT00525408 2012-03-12

HRPC

Cadila Pharnmaceuticals

Phase 2 Terminated
134 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT01215799 2011-12-15

PROACT

CytRx

Phase 2 Completed
23 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡